- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02532179
Subcutaneous Immunotherapy for Mouse in Adults (SCITMO)
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity. The study is designed to evaluate:
- the safety of this therapy when given by injection
- biomarkers of the immune response and
- whether the therapy would be effective in treating allergic asthma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to assess if treatment with mouse subcutaneous immunotherapy (SCIT), using the per protocol allergenic extract doses, is safe. This will be done by determining the rate of related adverse events and serious adverse events in the course of treatment.
Secondary objectives include:
- determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce a 3-fold increase in mouse-specific serum immunoglobulin E (IgE)
- determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce changes in the serum levels of mouse-specific immunoglobulin G (IgG) and immunoglobulin subclass 4 (IgG4).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Health System
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann and Robert Lurie Children's Hospital of Chicago
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Children's Center: Department of Allergy & Immunology
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System: Division of Allergy and Immunology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
Participants who meet any of the following criteria are not eligible for enrollment but may be reassessed. Participants are ineligible if they:
- Are pregnant or lactating. Females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception);
- Cannot perform spirometry at Screening;
Have an asthma severity classification at Recruitment of severe persistent, using the NAEPP classification, as evidenced by at least one of the following:
- Requires a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid;
- Have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months;
- Have been treated with depot steroids within the last 12 months;
- Have been hospitalized for asthma within the 6 months prior to recruitment;
- Have had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment.
- Do not have access to a phone (needed for scheduling appointments);
- Have received allergen immunotherapy (SLIT or SCIT) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study;
- Have previously been treated with anti-IgE therapy within 1 year of recruitment;
- Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study;
- Refuses to sign the Epinephrine Auto-injector Training Form.
EXCLUSION CRITERIA
Participants who meet any of the following criteria are not eligible for enrollment and may not be reassessed. Participants are ineligible if they:
- Do not primarily speak English;
- Plan to move from the area during the study period;
- Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher as defined per protocol;
- Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the participant;
- Are using tricyclic antidepressants or beta-adrenergic blocker drugs (both oral and topical);
- Have not received the seasonal Flu (Influenza) Vaccine if enrolling December through March.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mouse Allergenic Extract
Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
|
Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Reported Adverse Events (AEs)
Time Frame: Baseline (Pre-Treatment) through 24 Weeks of Treatment
|
Frequency of any AEs tabulated by preferred event term.
|
Baseline (Pre-Treatment) through 24 Weeks of Treatment
|
Number of Reported Serious Adverse Events (SAEs)
Time Frame: Baseline (Pre-Treatment) through 24 Weeks of Treatment
|
Frequency of any Serious Adverse Events (SAEs) throughout the duration of study participation.
|
Baseline (Pre-Treatment) through 24 Weeks of Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mouse-Specific IgE Antibodies
Time Frame: Baseline (Pre-Treatment) through Week 24
|
Serum Immunoglobulin E (IgE) is an antibody produced by the immune system. If a participant has an allergy, the immune system will respond to that particular allergen by producing IgE antibodies. These antibodies travel to cells that release chemicals, causing allergic reactions. This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgE versus post-baseline mouse-specific serum IgE. The numerator is the geometric mean post-baseline IgE and the denominator is baseline IgE. A ratio of greater than 1 would indicate an increase in IgE throughout the course of the study. |
Baseline (Pre-Treatment) through Week 24
|
Change in Mouse-Specific IgG Antibodies
Time Frame: Baseline (Pre-Treatment) to Week 24
|
Serum Immunoglobulin G (IgG) is an antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG antibodies. This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG versus post-baseline mouse-specific serum IgG. The numerator is the geometric mean post-baseline IgG and, the denominator is the baseline IgG. A ratio of greater than 1 would indicate an increase in IgG throughout the course of the study. |
Baseline (Pre-Treatment) to Week 24
|
Change in Mouse-Specific IgG4 Antibodies
Time Frame: Baseline (Pre-Treatment) to Week 24
|
Serum Immunoglobulin G4 (IgG4) is a subtype of antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG4 antibodies. This endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG4 versus post-baseline mouse-specific serum IgG4. The numerator is the geometric mean post-baseline IgG4 and, the denominator is the baseline IgG4. A ratio of greater than 1 would indicate an increase in IgG4 antibodies throughout the course of the study. |
Baseline (Pre-Treatment) to Week 24
|
Change in In-vitro Mouse Antigen Binding to B-cells
Time Frame: Baseline (Pre-Treatment) to Week 24
|
The plan was to analyze serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants to determine if treatment inhibits in-vitro mouse antigen binding to B-cells after 6-months of treatment with mouse SCIT, using the per protocol allergenic extract doses.
However, the Sponsor cancelled pursuit of mouse immunotherapy within its program at this time due to assay development complexities and cost; thus, there are no analyses/results for this endpoint/outcome.
|
Baseline (Pre-Treatment) to Week 24
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Robert Wood, M.D., Johns Hopkins Children's Center: Department of Allergy & Immunology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Otorhinolaryngologic Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Asthma
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
Other Study ID Numbers
- DAIT ICAC-26
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Mouse Allergenic Extract
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Inner-City Asthma ConsortiumCompleted
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | AllergyUnited States
-
Antigen Laboratories, Inc.Completed
-
Inmunotek S.L.Not yet recruitingAllergic Reaction | Allergic Skin Reaction | Allergy PollenSpain
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompleted
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Perennial Allergic RhinitisUnited States
-
Inmunotek S.L.Not yet recruitingAllergic Reaction | Allergic Skin Reaction | Allergy PollenSpain
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Rhinitis, Allergic, PerennialUnited States
-
Greer LaboratoriesCompletedAllergic RhinitisUnited States
-
Leti Pharma GmbHPierrel Research Europe GmbH; Laboratorios LETI SL (Study Medication); Labor...CompletedAllergic Rhinitis and/or Rhinoconjunctivitis +- Asthma | Immunotherapy, AllergenGermany, Lithuania, Poland